

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 207/16, A61K 31/40</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/15611</p> <p>(43) International Publication Date: 23 March 2000 (23.03.00)</p>
<p>(21) International Application Number: PCT/US99/18258</p> <p>(22) International Filing Date: 11 August 1999 (11.08.99)</p> <p>(30) Priority Data: 60/100,156 14 September 1998 (14.09.98) US</p> <p>(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BRYANS, Justin, Stephen [GB/GB]; Dean Cottage, 3 W. Wickham Road, Balsham CB1 6DZ (GB). EKHATO, Ihoezo, Victor [NG/US]; 2415 Tamarack Court, Ann Arbor, MI 48105 (US). HORWELL, David, Christopher [GB/GB]; 8 West Hill, Foxton, Cam- bridge CB2 6SZ (GB). LING, Rong [CN/US]; 1952 Traver Rd. #102, Ann Arbor, MI 48105 (US). RECEVEUR, Jean-Marie [FR/GB]; 93 Gwydir Street, Cambridge CB1 2LG (GB). WUSTROW, David, Juergen [US/US]; 5101 John Holmes Road, Ann Arbor, MI 48103 (US).</p> <p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.</p>		<p>(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS</p>		
<div style="text-align: center;"> <p>(I)</p> </div>		
<p>(57) Abstract</p> <p>Branched alkyl pyrrolidines of formula (I) are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders. Processes for the preparation and intermediates useful in the preparation are also disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS

BACKGROUND OF THE INVENTION

Compounds of formula




5 wherein R_1 is hydrogen or a lower alkyl radical and n is 4, 5, or 6 are known in United States Patent Number 4,024,175 and its divisional United States Patent Number 4,087,544. The uses disclosed are: protective effect against cramp induced by thiosemicarbazide; protective action against cardiazole cramp; the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas;
 10 and improvement in cerebral functions. The compounds are useful in geriatric patients. The patents are hereby incorporated by reference.

SUMMARY OF THE INVENTION

The compounds, prodrugs, and pharmaceutically acceptable salts are useful in a variety of disorders. The disorders include: convulsions such as in
 15 epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, inflammatory disorders such as arthritis, irritable bowel syndrome, and neuropathological disorders.

The compounds are those of formula



20 or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein R_1 is hydrogen or a straight or branched alkyl of from 1 to 5 carbons; R_2 is a straight or branched alkyl of from 1 to 5 carbons; and

-2-

R₁ and R₂ when taken together form a carbocyclic ring of from 3 to 7 atoms.

Preferred compounds are those wherein

R₁ is H, methyl, or ethyl; and

R₂ is methyl or ethyl.


5 The most preferred compounds are those wherein (cis)-4-isobutyl-pyrrolidine-3-carboxylic acid and (trans)-4-isobutyl-pyrrolidine-3-carboxylic acid.

Other preferred compounds are those wherein R₁ and R₂ are taken to form a carbocyclic ring of from 3 to 7 atoms.

10 More preferred compounds are those wherein R₁ and R₂ form a five or six membered ring.

Novel intermediates useful in the preparation of the final compounds are also encompassed by the invention.

Other compounds of the invention are those of Formula IA



IA

15 or a pharmaceutically acceptable salt thereof wherein R₄ is alkyl of 3 or 4 carbons. Such compounds are selected from:

trans-4-isopropylpyrrolidine-3-carboxylic acid;
trans-4-propyl-pyrrolidine-3-carboxylic acid; and
trans-4-butyl-pyrrolidine-3-carboxylic acid.

20 DETAILED DESCRIPTION OF THE INVENTION

The compounds of the instant invention and their pharmaceutically acceptable salts and prodrugs are as defined by Formula I above.

25 The term "alkyl" is a straight or branched group of from 1 to 5 carbon atoms including but not limited to methyl, ethyl, propyl, n-propyl, isopropyl, butyl, 2-butyl, tert-butyl, and pentyl.


Preferred groups are methyl and tert-butyl.

-3-

The stereocenters in Formula I can have independently be of either an R or S configuration.

Compounds of Formula I wherein the two substituents have a cis relative orientation about the pyrrolidine ring can be prepared in the following manner outlined in Scheme 1.


Scheme 1



Compounds of Formula I wherein the two substituents have a trans relative orientation about the pyrrolidine ring, can be prepared in the following manner outlined in Scheme 2.


-4-

Scheme 2




-5-

Scheme 3




-6-
Scheme 4



-7-

Scheme 5



Compound	R ₁	R ₂	2 (%)	3 (%)
a	CH ₃	H	100	90
b	CH ₃	CH ₃	28	84
c	C ₂ H ₅	H	95	78
d	i-Pr	H	79	88
e	n-Pr	H	72	88
f	i-Bu	H	99	86
g	H	i-Bu	41	85
h	n-Bu	H	82	85

Scheme 6




TABLE I




Structure	[3H]GAP Binding IC ₅₀ (μM)	NA Release % Inhibition @ 100 μM	Sys L IC ₅₀ (μM)	CITH % MPE 1h 2h	DBA 2 % Protect (time)	Vogel % of CI-1008
	0.140		25	48.9 19.9	100	63.7
gabapentin 						
pregabalin 	0.087		193	52.5 50.1	100 100	100
	0.120		>10,000	53 4.6	20 20	

TABLE 1 (Con't)





Structure	[3H]GAP Binding IC ₅₀ (μM)	NA Release % Inhibition @ 100 μM	Sys L IC ₅₀ (μM)	CITH % MPE 1h 2h	DBA 2 % Protect (time)	Vogel % of Cl-1008
 (+/-)	0.051			3 -15	0 0	
 (+/-)	0.700			23 3.3	0 0	
 (R,R)	0.015	16			20 40	0.63
 (S,S)	1.166	8				-0.63

TABLE I (Con't)







Structure	[3H]GAP Binding IC ₅₀ (μM)	NA Release % Inhibition @ 100 μM	Sys L IC ₅₀ (μM)	CITH % MPE 1h 2h	DBA 2 % Protect (time)	Vogel % of CI-1008
	3.101					
	1.192					
						

TABLE I (Con't)

Structure	[3H]GAP Binding IC ₅₀ (μM)	NA Release % Inhibition @ 100 μM	Sys L IC ₅₀ (μM)	CITH % MPE 1h 2h	DBA 2 % Protect (time)	Vogel % of Cl-1008
	0.543					
	0.030					
	0.064					

Since amino acids are amphoteric, pharmacologically compatible salts when R is hydrogen can be salts of appropriate inorganic or organic acids, for example, hydrochloric, sulphuric, phosphoric, acetic, oxalic, lactic, citric, malic, salicylic, malonic, maleic, succinic, and ascorbic. Starting from corresponding hydroxides or carbonates, salts with alkali metals or alkaline earth metals, for example, sodium, potassium, magnesium, or calcium are formed. Salts with quaternary ammonium ions can also be prepared with, for example, the tetramethyl-ammonium ion.

Prodrugs of compounds I-VIII are included in the scope of the instant invention. Aminoacyl-glycolic and -lactic esters are known as prodrugs of amino acids (Wermuth C.G., *Chemistry and Industry*, 1980:433-435). The carbonyl group of the amino acids can be esterified by known means. Prodrugs and soft drugs are known in the art (Palomino E., *Drugs of the Future*, 1990;15(4):361-368). The last two citations are hereby incorporated by reference.

The effectiveness of an orally administered drug is dependent upon the drug's efficient transport across the mucosal epithelium and its stability in entero-hepatic circulation. Drugs that are effective after parenteral administration but less effective orally, or whose plasma half-life is considered too short, may be chemically modified into a prodrug form.

A prodrug is a drug which has been chemically modified and may be biologically inactive at its site of action, but which may be degraded or modified by one or more enzymatic or other in vivo processes to the parent bioactive form.

This chemically modified drug, or prodrug, should have a different pharmacokinetic profile to the parent, enabling easier absorption across the mucosal epithelium, better salt formulation and/or solubility, improved systemic stability (for an increase in plasma half-life, for example). These chemical modifications may be

- 1) ester or amide derivatives which may be cleaved by, for example, esterases or lipases. For ester derivatives, the ester is derived from the carboxylic acid moiety of the drug molecule by known means. For amide derivatives, the amide may be derived from the carboxylic acid moiety or the amine moiety of the drug molecule by known means.

- 2) peptides which may be recognized by specific or nonspecific proteinases. A peptide may be coupled to the drug molecule via amide bond formation with the amine or carboxylic acid moiety of the drug molecule by known means.
- 3) derivatives that accumulate at a site of action through membrane selection of a prodrug form or modified prodrug form,
- 4) any combination of 1 to 3.

Current research in animal experiments has shown that the oral absorption of certain drugs may be increased by the preparation of "soft" quaternary salts. The quaternary salt is termed a "soft" quaternary salt since, unlike normal quaternary salts, e.g., $R-N^+(CH_3)_3$, it can release the active drug on hydrolysis.

"Soft" quaternary salts have useful physical properties compared with the basic drug or its salts. Water solubility may be increased compared with other salts, such as the hydrochloride, but more important there may be an increased absorption of the drug from the intestine. Increased absorption is probably due to the fact that the "soft" quaternary salt has surfactant properties and is capable of forming micelles and unionized ion pairs with bile acids, etc., which are able to penetrate the intestinal epithelium more effectively. The prodrug, after absorption, is rapidly hydrolyzed with release of the active parent drug.

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof. For example, the compound of Example 1 is a mixture of all four possible stereoisomers. The compound of Example 6 is one of the isomers. The configuration of the cyclohexane ring carbon centers may be R or S in these compounds where a configuration can be defined.

The radioligand binding assay using [3H]gabapentin and the $\alpha_2\delta$ subunit derived from porcine brain tissue was used (Gee N.S., Brown J.P., Dissanayake

-15-

V.U.K., Offord J., Thurlow R., Woodruff G.N., "The Novel Anti-convulsant Drug, Gabapentin, Binds to the $\alpha_2\delta$ Subunit of a Calcium Channel," *J. Biol. Chem.*, 1996;271:5879-5776).

- 5 Compounds can also be assayed for biological activity using a [3H]gabapentin binding assay as described in Suman Chauhan N., et al., *Eur. J. Pharmacol.*, 1993;244:293-301.




TABLE 2		
Compound	Structure	IC ₅₀ (μ M) at $\alpha_2\delta$ Binding Site
Example 1		0.135
Example 2		0.044

Table 2 above shows the binding affinity of the compounds of the invention to the $\alpha_2\delta$ subunit.

- 10 The compounds of the invention are compared to Neurontin®, a marketed drug effective in the treatment of such disorders as epilepsy. Neurontin® is 1-(aminomethyl)-cyclohexaneacetic acid of structural formula



- 15 Gabapentin (Neurontin®) is about 0.10 to 0.12 μ M in this assay. The compounds of the instant invention are expected, therefore, to exhibit pharmacologic properties comparable to gabapentin. For example, as agents for convulsions, anxiety, and pain.

-16-

The present invention also relates to therapeutic use of the compounds of the mimetic as agents for neurodegenerative disorders.

Such neurodegenerative disorders are, for example, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis.

5 The present invention also covers treating neurodegenerative disorders termed acute brain injury. These include but are not limited to: stroke, head trauma, and asphyxia.

Stroke refers to a cerebral vascular disease and may also be referred to as a cerebral vascular incident (CVA) and includes acute thromboembolic stroke.
10 Stroke includes both focal and global ischemia. Also, included are transient cerebral ischemic attacks and other cerebral vascular problems accompanied by cerebral ischemia. A patient undergoing carotid endarterectomy specifically or other cerebrovascular or vascular surgical procedures in general, or diagnostic vascular procedures including cerebral angiography and the like.

15 Other incidents are head trauma, spinal cord trauma, or injury from general anoxia, hypoxia, hypoglycemia, hypotension as well as similar injuries seen during procedures from embolus, hyperfusion, and hypoxia.

The instant invention would be useful in a range of incidents, for example, during cardiac bypass surgery, in incidents of intracranial hemorrhage, in perinatal asphyxia, in cardiac arrest, and status epilepticus.
20

Pain refers to acute as well as chronic pain.

Acute pain is usually short-lived and is associated with hyperactivity of the sympathetic nervous system. Examples are postoperative pain and allodynia.

Chronic pain is usually defined as pain persisting from 3 to 6 months and includes somatogenic pains and psychogenic pains. Other pain is nociceptive.
25

Still other pain is caused by injury or infection of peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies. Neuropathic pain includes, but is not limited to pain caused by nerve injury such as, for example, the pain diabetics suffer from.
30

-17-

Psychogenic pain is that which occurs without an organic origin such as low back pain, atypical facial pain, and chronic headache.

Other types of pain are: inflammatory pain, osteoarthritic pain, trigeminal neuralgia, cancer pain, diabetic neuropathy, restless leg syndrome, acute herpetic
5 and postherpetic neuralgia, causalgia, brachial plexus avulsion, occipital neuralgia, gout, phantom limb, burn, and other forms of neuralgia, neuropathic and idiopathic pain syndrome.

A skilled physician will be able to determine the appropriate situation in which subjects are susceptible to or at risk of, for example, stroke as well as
10 suffering from stroke for administration by methods of the present invention.

The compounds of the invention are also expected to be useful in the treatment of depression. Depression can be the result of organic disease, secondary to stress associated with personal loss, or idiopathic in origin. There is a strong tendency for familial occurrence of some forms of depression suggesting a
15 mechanistic cause for at least some forms of depression. The diagnosis of depression is made primarily by quantification of alterations in patients' mood. These evaluations of mood are generally performed by a physician or quantified by a neuropsychologist using validated rating scales, such as the Hamilton Depression Rating Scale or the Brief Psychiatric Rating Scale. Numerous other
20 scales have been developed to quantify and measure the degree of mood alterations in patients with depression, such as insomnia, difficulty with concentration, lack of energy, feelings of worthlessness, and guilt. The standards for diagnosis of depression as well as all psychiatric diagnoses are collected in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) referred to
25 as the DSM-IV-R manual published by the American Psychiatric Association, 1994.

GABA is an inhibitory neurotransmitter with the central nervous system. Within the general context of inhibition, it seems likely that GABA-mimetics might decrease or inhibit cerebral function and might therefore slow function and
30 decrease mood leading to depression.

The compounds of the instant invention may produce an anticonvulsant effect through the increase of newly created GABA at the synaptic junction. If gabapentin does indeed increase GABA levels or the effectiveness of GABA at

-18-

the synaptic junction, then it could be classified as a GABA-mimetic and might decrease or inhibit cerebral function and might, therefore, slow function and decrease mood leading to depression.

5 The fact that a GABA agonist or GABA-mimetic might work just the opposite way by increasing mood and thus, be an antidepressant, is a new concept, different from the prevailing opinion of GABA activity heretofore.

The compounds of the instant invention are also expected to be useful in the treatment of anxiety and of panic as demonstrated by means of standard pharmacological procedures.

10

MATERIAL AND METHODS

Carrageenin-Induced Hyperalgesia

Nociceptive pressure thresholds were measured in the rat paw pressure test using an analgesymeter (Randall-Selitto method: Randall L.O. and Selitto J.J., "A method for measurement of analgesic activity on inflamed tissue," *Arch. Int. Pharmacodyn.*, 1957;4:409-419). Male Sprague-Dawley rats (70-90 g) were
15 trained on this apparatus before the test day. Pressure was gradually applied to the hind paw of each rat and nociceptive thresholds were determined as the pressure (g) required to elicit paw withdrawal. A cutoff point of 250 g was used to prevent any tissue damage to the paw. On the test day, two to three baseline measurements
20 were taken before animals were administered 100 μ L of 2% carrageenin by intraplantar injection into the right hind paw. Nociceptive thresholds were taken again 3 hours after carrageenin to establish that animals were exhibiting hyperalgesia. Animals were dosed with either gabapentin (3-300 mg, s.c.), morphine (3 mg/kg, s.c.) or saline at 3.5 hours after carrageenin and nociceptive
25 thresholds were examined at 4, 4.5, and 5 hours postcarrageenin.

(R)-2-Aza-spiro[4.5]decane-4-carboxylic acid hydrochloride was tested in the above carrageenan-induced hyperalgesia model. The compound was dosed orally at 30 mg/kg, and 1 hour postdose gave a percent of maximum possible effect (MPE) of 53%. At 2 hours postdose, it gave only 4.6% of MPE.

-19-

Compounds can be tested for antihyperalgesic activity using the method described in Bennett G. J., et al., *Pain*, 1988;33:87-107.

Mouse Light/Dark Box

5 The apparatus is an open-topped box, 45 cm long, 27 cm wide, and 27 cm high, divided into a small (2/5) and a large (3/5) area by a partition that extended 20 cm above the walls (Costall B., et al., "Exploration of mice in a black and white box: validation as a model of anxiety," *Pharmacol. Biochem. Behav.*, 1989;32:777-785).

10 There is a 7.5 × 7.5 cm opening in the center of the partition at floor level. The small compartment is painted black and the large compartment white. The white compartment is illuminated by a 60-W tungsten bulb. The laboratory is illuminated by red light. Each mouse is tested by placing it in the center of the white area and allowing it to explore the novel environment for 5 minutes. The time spent in the illuminated side is measured (Kilfoil T., et al., "Effects of
15 anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice," *Neuropharmacol.*, 1989;28:901-905).

Rat Elevated X-Maze

A standard elevated X-maze (Handley S.L., et al., "Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-
20 motivated behavior," *Naunyn-Schiedeberg's Arch. Pharmacol.*, 1984;327:1-5), was automated as previously described (Field, et al., "Automation of the rat elevated X-maze test of anxiety," *Br. J. Pharmacol.*, 1991;102(Suppl.):304P). The animals are placed on the center of the X-maze facing one of the open arms. For determining anxiolytic effects the entries and time spent on the end half sections
25 of the open arms is measured during the 5-minute test period (Costall, et al., "Use of the elevated plus maze to assess anxiolytic potential in the rat," *Br. J. Pharmacol.*, 1989;96(Suppl.):312p).

Marmoset Human Threat Test

30 The total number of body postures exhibited by the animal towards the threat stimulus (a human standing approximately 0.5 m away from the marmoset

-20-

cage and staring into the eyes of the marmoset) is recorded during the 2-minute test period. The body postures scored are slit stares, tail postures, scent marking of the cage/perches, piloerection, retreats, and arching of the back. Each animal is exposed to the threat stimulus twice on the test day before and after drug treatment. The difference between the two scores is analyzed using one-way analysis of variance followed by Dunnett's t-test. All drug treatments are carried out SC at least 2 hours after the first (control) threat. The pretreatment time for each compound is 40 minutes.

Rat Conflict Test

Rats are trained to press levers for food reward in operant chambers. The schedule consists of alternations of four 4-minute unpunished periods on variable interval of 30 seconds signaled by chamber lights on and three 3-minute punished periods on fixed ratio 5 (by footshock concomitant to food delivery) signaled by chamber lights off. The degree of footshock is adjusted for each rat to obtain approximately 80% to 90% suppression of responding in comparison with unpunished responding. Rats receive saline vehicle on training days.

DBA2 Mouse Model of Anticonvulsant Efficacy

All procedures were carried out in compliance with the NIH Guide for the Care and Use of Laboratory Animals under a protocol approved by the Parke-Davis Animal Use Committee. Male DBA/2 mice, 3 to 4 weeks old were obtained from Jackson Laboratories Bar Harbour, Maine. Immediately before anticonvulsant testing, mice were placed upon a wire mesh, 4 inches square, suspended from a steel rod. The square was slowly inverted through 180° and mice observed for 30 seconds. Any mouse falling from the wire mesh was scored as ataxic (Coughenour L.L., McLean J.R., Parker R.B., "A new device for the rapid measurement of impaired motor function in mice," *Pharm. Biochem. Behav.*, 1977;6(3):351-3). Mice were placed into an enclosed acrylic plastic chamber (21 cm height, approximately 30 cm diameter) with a high-frequency speaker (4 cm diameter) in the center of the top lid. An audio signal generator (Protek model B-810) was used to produce a continuous sinusoidal tone that was swept linearly in frequency between 8 kHz and 16 kHz once each 10 msec. The

-21-

average sound pressure level (SPL) during stimulation was approximately 100 dB at the floor of the chamber. Mice were placed within the chamber and allowed to acclimatize for one minute. DBA/2 mice in the vehicle-treated group responded to the sound stimulus (applied until tonic extension occurred, or for a maximum of 60 sec) with a characteristic seizure sequence consisting of wild running followed by clonic seizures, and later by tonic extension, and finally by respiratory arrest and death in 80% or more of the mice. In vehicle-treated mice, the entire sequence of seizures to respiratory arrest lasts approximately 15 to 20 seconds. The incidence of all the seizure phases in the drug-treated and vehicle-treated mice was recorded, and the occurrence of tonic seizures were used for calculating anticonvulsant ED₅₀ values by probit analysis (Litchfield J.T., Wilcoxon F. "A simplified method for evaluating dose-effect experiments," *J. Pharmacol.*, 1949;96:99-113). Mice were used only once for testing at each dose point. Groups of DBA/2 mice (n = 5-10 per dose) were tested for sound-induced seizure responses 2 hours (previously determined time of peak effect) after given drug orally. All drugs in the present study were dissolved in distilled water and given by oral gavage in a volume of 10 mL/kg of body weight. Compounds that are insoluble will be suspended in 1% carboxymethocellulose. Doses are expressed as weight of the active drug moiety.

The compounds of the instant invention are also expected to be useful in the treatment of pain and phobic disorders (*Am. J. Pain Manag.*, 1995;5:7-9).

The compounds of the instant invention are also expected to be useful in treating the symptoms of manic, acute or chronic, single upside, or recurring depression. They are also expected to be useful in treating and/or preventing bipolar disorder (United States Patent Number 5,510,381).

Models of Irritable Bowel Syndrome

TNBS-Induced Chronic Visceral Allodynia In Rats

Injections of trinitrobenzene sulfonic (TNBS) into the colon have been found to induce chronic colitis. In human, digestive disorders are often associated with visceral pain. In these pathologies, the visceral pain threshold is decreased

indicating a visceral hypersensitivity. Consequently, this study was designed to evaluate the effect of injection of TNBS into the colon on visceral pain threshold in a experimental model of colonic distension.

Materials and Methods

5 **Animals and surgery**

Male Sprague-Dawley rats (Janvier, Le Genest-St-Ilse, France) weighing 340-400 g are used. The animals are housed 3 per cage in a regulated environment (20 ± 1°C, 50 ± 5% humidity, with light 8:00 am to 8:00 pm). Under anesthesia (ketamine 80 mg/kg i.p; acepromazin 12 mg/kg ip), the injection of TNBS (50 mg/kg) or saline (1.5 mL/kg) is performed into the proximal colon (1 cm from the cecum). After the surgery, animals are individually housed in polypropylene cages and kept in a regulated environment (20 ± 1°C, 50 ± 5% humidity, with light 8:00 am to 8:00 pm) during 7 days.

15 **Experimental procedure**

At Day 7 after TNBS administration, a balloon (5-6 cm length) is inserted by anus and kept in position (tip of balloon 5 cm from the anus) by taping the catheter to the base of the tail. The balloon is progressively inflated by step of 5 mm Hg, from 0 to 75 mm Hg, each step of inflation lasting 30 seconds. Each cycle of colonic distension is controlled by a standard barostat (ABS, St-Dié, France). The threshold corresponds to the pressure which produced the first abdominal contraction and the cycle of distension is then discontinued. The colonic threshold (pressure expressed in mm Hg) is determined after performance of four cycles of distension on the same animal.

25 **Determination of the activity of the compound**

Data is analyzed by comparing test compound-treated group with TNBS-treated group and control group. Mean and sem are calculated for each group. The antiallodynic activity of the compound is calculated as follows:

$$\text{Activity (\%)} = (\text{group C} - \text{group T}) / (\text{group A} - \text{group T})$$

Group C: mean of the colonic threshold in the control group

-23-

Group T: mean of the colonic threshold in the TNBS-treated group

Group A: mean of the colonic threshold in the test compound-treated group

Statistical analysis

5 Statistical significance between each group was determined by using a one-way ANOVA followed by Student's unpaired t-test. Differences were considered statistically significant at $p < 0.05$.

Compounds

10 TNBS is dissolved in EtOH 30% and injected under a volume of 0.5 mL/rat. TNBS is purchased from Fluka.

Oral administration of the test compound or its vehicle is performed 1 hour before the colonic distension cycle.

Sub-cutaneous administration of the test compound or its vehicle is performed 30 minutes before the colonic distension cycle.

15 The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be
20 administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I.

25 For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders,
30 preservatives, tablet disintegrating agents, or an encapsulating material.

-24-

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

5 In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

10 The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges
15 can be used as solid dosage forms suitable for oral administration.

20 For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

25 Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.

30 Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.

-25-

Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

5 The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit
10 dosage form can be a capsules, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

 The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1 g according to the particular application and the potency of the active component. In medical use the drug may be administered
15 three times daily as, for example, capsules of 100 or 300 mg. The composition can, if desired, also contain other compatible therapeutic agents.

 In therapeutic use, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily. A daily dose range of about 0.01 mg to about 100 mg/kg is
20 preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased
25 by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

 The following examples are illustrative of the synthetic procedures for making the intermediates and final products of the instant invention. They are not
30 intended to limit the scope of the invention.

EXAMPLE 1

(cis)-4-Isobutyl-pyrrolidine-3-carboxylic acid (see Scheme 3)

Step 1: Synthesis of 1,1-Dibromo-4-methyl-pent-1-ene

To a stirred solution of carbon tetrabromide (30 g, 90.63 mmol) in dichloromethane (400 mL) at -10°C was added triphenylphosphine (60 g, 229 mmol) in portions. Internal temperature was kept below 5°C during the addition, and it was stirred for additional 30 minutes at this temperature after the addition was completed. Isovaleraldehyde **1** (9.4 mL, 87.6 mmol) in methylene chloride (50 mL) was added slowly via a syringe, and the reaction was stirred for 3 hours during which the temperature did not rise above 5°C. After the solvent was removed on a rotary evaporator, pentane (600 mL) was added to the residue. The solid which separated was removed by filtration. Evaporation of solvent gave a light oil which was chromatographed on a silica gel column. The pure compound was eluted with pet ether to afford 1,1-dibromo-4-methyl-pent-1-ene **6** (16.5 g, 78%).
NMR (CDCl₃): δ 6.38 (triplet, 1H), 1.95 (triplet, 2H), 1.70 (m, 1H), and 0.89 (d, 6H).

Step 2: Synthesis of 5-Methyl-hex-2-ynoic acid ethyl ester

1,1-Dibromo-4-methyl-pent-1-ene **6** (40 g, 165.9 mmol) was dissolved in dry THF (120 mL) and cooled to -78°C. While stirring, *n*-butyllithium (1.6 M solution in hexane, 190.8 mL, 305 mmol) was added dropwise in a few minutes. After 1 hour, ethyl chloroformate (15 mL, 154.5 mmol) was added, and the reaction was stirred overnight during which it warmed to room temperature. It was poured onto water and extracted with ether (3 × 250 mL), dried on magnesium sulfate and evaporated. The light oil was flash chromatographed on a silica gel column, and the compound was eluted with 10% ether in pet ether to afford 5-methyl-hex-2-ynoic acid ethyl ester **7** (23.6 g, 92%).
NMR (CDCl₃): δ 4.14 (m, 2H), 2.16 (d, 2H), 1.85 (m, 1H), 1.24 (triplet, 3H), and 0.94 (d, 6H).

-27-

Step 3: Synthesis of (Z)-5-Methyl-hex-2-enoic acid ethyl ester

5-Methyl-hex-2-ynoic acid ethyl ester 7 (20.97 g) in THF (540 mL), pyridine (60 mL), and 5% Pd/BaSO₄ (1:10 g) was hydrogenated in 3.25 hours.

The solvent was evaporated, and the light oil was chromatographed on a silica gel column. After recovering some unreacted acetylene, the olefin was eluted with 5% ether in pet ether to give pure fractions of (Z)-5-methyl-hex-2-enoic acid ethyl ester 8 (12.0 g).

NMR (CDCl₃): δ 6.22 (m, 1H), 5.74 (d, 1H), 4.10 (m, 2H), 2.51 (triplet, 2H), 1.67 (m, 1H), 1.24 (triplet, 3H), and 1.16 (d, 6H).

10 N-Benzyl-N-(methoxymethyl)trimethylsilylmethylamine (Reagent for Step 4)

n-Butyllithium (1.6 M solution in hexane, 34.85 mL, 55.76 mmol) was added to *N*-benzyltrimethylsilylmethylamine (10 g, 55.76 mmol) in dry THF (140 mL) and stirred at -78°C under nitrogen atmosphere. After 45 minutes, methoxymethyl chloride (4.3 mL, 55.76 mmol) in THF (6 mL) was added and then stirred for another 3 hours. The THF was evaporated, and the residue was dissolved in hexane, washed with water, and dried over sodium sulfate. The solvent was evaporated to give under reduced pressure to give *N*-benzyl-*N*-(methoxymethyl)trimethylsilylmethylamine (10 g).

Step 4: (cis)-1-Benzyl-4-isobutyl-pyrrolidine-3-carboxylic acid ethyl ester

20 *N*-Benzyl-*N*-(methoxymethyl)trimethylsilylmethylamine (4.0 g, 16.8 mmol), followed by TFA (1.0 M solution in CH₂Cl₂, 1.0 mL, 1 mmol) were added to a solution of (Z)-5-methyl-hex-2-enoic acid ethyl ester 8 (3.0 g, 19.2 mmol) in methylene chloride (30 mL) maintained at -5°C under nitrogen atmosphere. After 15 minutes, the bath was removed and stirring was continued overnight. The reaction mixture was washed with saturated NaHCO₃ (10 mL), water (15 mL), brine (20 mL), and dried. The product was purified by chromatography on silica gel, and compound was eluted with 20% ethyl acetate in hexane to give (cis)-1-benzyl-4-isobutyl-pyrrolidine-3-carboxylic acid ethyl ester 9 as an oil (2.25 g, 41%).

-28-

Step 5: Synthesis of (cis)-4-Isobutyl-pyrrolidine-3-carboxylic acid

(cis)-1-Benzyl-4-isobutyl-pyrrolidine-3-carboxylic acid ethyl ester 9 (2.25 g, 7.78 mmol) in ethanol (75 mL) and 20% Pd/C (210 mg) was hydrogenated for 5.5 hours. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated to give [3R-(cis)]-4-isobutyl-pyrrolidine-3-carboxylic acid ethyl ester 10 as an oil. Proton NMR showed the absence of a benzyl group. To the 10 was added 6N HCl (20 mL), and the solution was refluxed overnight. After the solvent was evaporated at reduced pressure crude product was loaded onto a column of Dowax 50WX8-100 ion-exchange resin (30 g) which had been pre-washed to neutral (pH-7) with HPLC grade water. The resin was again washed to pH-7, followed by elution of the compound with 0.5N ammonium hydroxide solution. The solvent was evaporated, and the product was crystallized from methanol-ether to give (cis)-4-isobutyl-pyrrolidine-3-carboxylic acid 11 (470 mg). Analysis by tlc (8% NH₄OH in 95% ethanol, visualized with ninhydrin) indicated the presence of minor fast chromatographic spot (*trans*-isomer). The mixture was adsorbed onto silica gel and chromatographed on a Biotage Flash system. Compound was eluted with 5% NH₄OH in 95% ethanol. After evaporation of solvent, the product was converted to the HCl salt and reprocessed on ion-exchange column, followed by crystalization from methanol-ether to give (cis)-4-isobutyl-pyrrolidine-3-carboxylic acid 11 (320 mg). ¹H NMR (400 MHz, CD₃OD): δ 3.46 (dd, 1H), 3.31 (dd, 1H), 3.18 (dd, 1H), 3.15 (m, 1H), 2.49 (m, 1H), 1.63 (m, 1H), 1.47 (m, 1H), 1.25 (m, 1H), and 0.88 (6H). Anal. Calcd for C₉H₁₇NO₂: C, 63.13; H, 10.01; N, 8.18. Found: C, 62.86; H, 9.82; N, 8.05.

EXAMPLE 2

[trans]-4-Isobutyl-pyrrolidine-3-carboxylic acid (See Scheme 4)Step 1: (E)-5-Methyl-hex-2-enoic acid ester

Sodium hydride (60% dispersion in oil) (3.87 g, 96.7 mmol) was washed with pentane and stirred in dimethoxyethane (80 mL). While cooling in ice bath, a

-29-

solution of triethyl phosphonoacetate (21.7 g, 96.7 mmol) was added slowly in 15 minutes. The reaction was stirred for additional 15 minutes and isovaleraldehyde **1** (31 mL, 290 mmol) in dimethoxyethane (20 mL) was added in one portion. It was refluxed overnight, concentrated, and hexane/water (500 mL, 3/2v/v) was added. The organic portion was separated, washed with water (200 mL), brine (2 × 200 mL) and dried on magnesium sulfate. Evaporation of solvent gave an oil which was purified by flash chromatography on silica gel. The compound was eluted with 30% methylene chloride in pet ether to give (E)-5-methyl-hex-2-enoic acid ester **2** as a clear liquid (13.2 g).

NMR (CDCl₃): δ 6.89 (m, 1H), 5.75 (d, 1H), 4.14 (m, 2H), 2.05 (m, 2H), 1.69 (m, 1H), 1.25 (triplet, 3H), and 0.88 (d, 6H).

Step 2: Synthesis of [trans]-1-Benzyl-4-isobutyl-pyrrolidine-3-carboxylic acid ethyl ester

N-Benzyl-*N*-(methoxymethyl)trimethylsilylmethylamine (2.84 g, 12 mmol), followed by TFA (1.0 M solution in CH₂Cl₂, 1.0 mL, 1 mmol) were added to a solution of (E)-5-methyl-hex-2-enoic acid ethyl ester (1.56 g, 10.0 mmol) in methylene chloride (30 mL) maintained at -5°C under nitrogen atmosphere. After 15 minutes, the bath was removed and stirring was continued overnight. Saturated sodium bicarbonate was added, and the organic portion was separated, washed with brine, and dried. The product was purified by chromatography on silica gel, and compound was eluted with 20% ethyl acetate in hexane to give (trans)-1-Benzyl-4-isobutyl-pyrrolidine-3-carboxylic acid ethyl ester **3** as an oil (1.28 g, 44%).

NMR (CDCl₃): δ 7.28 (m, 5H), 4.09 (m, 2H), 3.56 (q, 2H), 2.81 (m, 2H), 2.69 (triplet, 1H), 2.51 (m, 2H), 2.18 (triplet, 1H), 1.51 (m, 1H) 1.38 (m, 1H), 1.27 (m, 1H), 1.20 (triplet, 3H), and 0.83 (d, 6H).

Step 3: [trans]-4-Isobutyl-pyrrolidine-3-carboxylic acid

(trans)-1-Benzyl-4-isobutyl-pyrrolidine-3-carboxylic acid ethyl ester **3** (1.28 g, 4.42 mmol) in ethanol (75 mL) and 20% Pd/C (210 mg) was hydrogenated for 5.5 hours. The reaction mixture was filtered through a pad of

-30-

Celite, and the filtrate was concentrated to give [3R-(trans)]-4-isobutyl-pyrrolidine-3-carboxylic acid ethyl ester **4** as an oil. Proton NMR (CDCl_3): δ 4.13 (m, 2H), 3.18 (m, 1H), 3.15 (m, 1H), 3.08 (m, 1H), 2.67 (brs, 1H), 2.46 (m, 2H), 2.34 (m, 1H), 1.55 (m, 1H), 1.37 (m, 1H), 1.25 (triplet, 3H) and 0.87 (q, 6H) showed the absence of a benzyl group. To the residue was added 6N HCl (20 mL), and the solution was refluxed overnight. After the solvent was evaporated at reduced pressure, crude product was loaded onto a column of Dowax 50WX8-100 ion-exchange resin (28 g) which had been pre-washed to neutral (pH-7) with hplc grade water. The resin was again washed to pH-7, followed by elution of the compound with 0.5N ammonium hydroxide solution. The fractions were monitored by tlc (8% NH_4OH in 95% ethanol, visualized with ninhydrin). The solvent was evaporated and the compound crystallized from methanol-ether to give (trans)-4-isobutyl-pyrrolidine-3-carboxylic acid **5** (280 mg). ^1H NMR (400 MHz, CD_3OD): δ 3.44 (dd, 1H), 3.37 (d, 2H), 2.78 (dd, 1H), 2.52 (m, 2H), 1.60 (m, 1H), 1.51 (m, 1H), 1.26 (m, 1H), 0.89 (6H).
Anal. Calcd. for $\text{C}_9\text{H}_{17}\text{NO}_2$:

C, 63.13; H, 10.01; N, 8.18.

Found: C, 62.79; H, 9.45; N, 8.02.

General Procedure for the Preparation of 1-Benzyl- 4-alkylpyrrolidine-3-carboxylic acid ethyl ester 2a-2h

To a stirred solution of α,β -unsaturated carboxylic acid ethyl ester **1a-1h** (11.70 mmol) in toluene (20 mL) was added N-benzyl-N-(methoxymethyl) trimethylsilylmethylamine (3.33 g, 14.10 mmol) at 0°C under N_2 . After 20 minutes, a solution of TFA (1 M in CH_2Cl_2 , 1.17 mmol) was added slowly at 0°C . The mixture was stirred at 0°C for 30 minutes and then at 22°C for an additional 12 hours. The reaction was quenched with H_2O , extracted with CHCl_3 , then dried over MgSO_4 . The solvent was evaporated to dryness, and the oily residue was subjected to column chromatography (silica gel, hexanes:ether=6:1) to give **2a-2h** as a colorless oil.

-31-

trans-1-Benzyl-4-methylpyrrolidine-3-carboxylic acid ethyl ester (2a). yield 100%; ^1H NMR (CDCl_3): δ 1.07 (d, $J = 6.6$ Hz, 3 H, CH_3), 1.18 (t, $J = 7.1$ Hz, 3 H, CH_2CH_3), 2.13-2.17 (m, 1 H, pyrrolidine ring), 2.40-2.50 (m, 2 H, pyrrolidine ring), 2.68-2.82 (m, 3 H, pyrrolidine ring), 3.48-3.59 (ABq, $J = 32.9$ Hz, 2 H, CH_2Ph), 4.04-4.09 (q, $J = 7.1$ Hz, 2 H, CH_2CH_3), 7.17-7.25 (m, 5 H, aromatic ring); ^{13}C (CDCl_3): δ 14.24, 19.74, 36.78, 50.65, 56.64, 60.09, 60.44, 61.63, 126.87, 128.19, 128.66, 138.98, 174.67; MS (CI) m/z 248 ($\text{M}+1$) $^+$. Anal. ($\text{C}_{15}\text{H}_{21}\text{NO}_2$) C, H, N.

1-Benzyl-4,4-dimethylpyrrolidine-3-carboxylic acid ethyl ester (2b). yield 28%; ^1H NMR (CDCl_3): δ 0.93 (s, 3 H, CH_3), 1.17 (s, 3 H, CH_3), 1.17-1.21 (t, $J = 7.0$ Hz, 3 H, CH_2CH_3), 2.20-2.87 (m, 5 H, pyrrolidine ring), 3.50-3.59 (ABq, $J = 26.2$ Hz, 2 H, CH_2Ph), 4.03-4.14 (m, 2 H, CH_2CH_3), 7.13-7.30 (m, 5 H, aromatic ring); ^{13}C (CDCl_3): δ 14.41, 24.15, 29.59, 41.49, 53.45, 55.84, 60.14, 60.18, 68.14, 126.82, 128.20, 128.55, 139.41, 173.33; MS (CI) m/z 262 ($\text{M}+1$) $^+$. Anal. ($\text{C}_{16}\text{H}_{23}\text{NO}_2$) C, H, N.

trans-1-Benzyl-4-ethylpyrrolidine-3-carboxylic acid ethyl ester (2c). yield 95%; ^1H NMR (CDCl_3): δ 0.86 (t, $J = 7.3$ Hz, 3 H, CH_2CH_3), 1.21 (t, $J = 7.1$ Hz, 3 H, OCH_2CH_3), 1.37-1.57 (m, 2 H, CH_2CH_3), 2.22-2.79 (m, 5 H, pyrrolidine ring), 3.51-3.64 (ABq, $J = 39.3$ Hz, 2 H, CH_2Ph), 4.08-4.13 (m, 2 H, OCH_2CH_3), 7.23-7.29 (m, 5 H, aromatic ring); ^{13}C (CDCl_3): δ 12.46, 14.25, 28.05, 43.73, 48.97, 56.84, 59.72, 60.07, 60.49, 126.89, 128.21, 128.64, 139.02, 175.01; MS (CI) m/z 262 ($\text{M}+1$) $^+$. Anal. ($\text{C}_{16}\text{H}_{23}\text{NO}_2$) C, H, N.

trans-1-Benzyl-4-isopropylpyrrolidine-3-carboxylic acid ethyl ester (2d). yield 79%; ^1H NMR (CDCl_3): δ 0.84-0.88 (m, 6 H, CH_3 , CH_3), 1.20-1.22 (t, $J = 8.0$ Hz, 3 H, CH_2CH_3), 1.54-1.62 (m, 1 H, $\text{CH}(\text{CH}_3)_2$), 2.24-2.32 (m, 2 H, pyrrolidine ring), 2.63-2.69 (m, 2 H, pyrrolidine ring), 2.74-2.80 (m, 2 H,

-32-

pyrrolidine ring), 3.47-3.65 (ABq, $J = 56.4$ Hz, 2 H, CH_2Ph), 4.06-4.14 (m, 2 H, CH_2CH_3), 7.19-7.30 (m, 5 H, aromatic ring); $^{13}\text{C}(\text{CDCl}_3)$: δ 14.19, 20.59, 20.81, 32.20, 47.16, 48.67, 57.56, 58.23, 59.99, 60.45, 126.82, 128.17, 128.54, 139.05, 175.33; MS (CI) m/z 276 ($M+1$)⁺. Anal. ($\text{C}_{17}\text{H}_{25}\text{NO}_2$) C, H, N.

5 ***trans*-1-Benzyl-4-propylpyrrolidine-3-carboxylic acid ethyl ester (2e).** yield 72%; ^1H NMR (CDCl_3): δ 0.84-0.88 (t, $J = 7.1$ Hz, 3 H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 1.20-1.24 (t, $J = 7.1$ Hz, 3 H, CH_2CH_3), 1.26-1.54 (m, 4 H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 2.21-2.82 (m, 6 H, pyrrolidine ring), 3.51-3.64 (ABq, $J = 40.6$ Hz, 2 H, CH_2Ph), 4.07-4.16 (m, 2 H, CH_2CH_3), 7.19-7.31 (m, 5 H, aromatic ring); $^{13}\text{C}(\text{CDCl}_3)$:
10 δ 14.09, 14.22, 21.13, 37.51, 41.74, 49.25, 56.75, 59.98, 60.05, 60.43, 126.84, 128.18, 128.61, 139.01, 174.95; MS (CI) m/z 276 ($M+1$)⁺. Anal. ($\text{C}_{17}\text{H}_{25}\text{NO}_2$) C, H, N.

***trans*-1-Benzyl-4-isobutylpyrrolidine-3-carboxylic acid ethyl ester (2f).** yield 99%; ^1H NMR (CDCl_3): δ 0.83-0.88 (d, $J = 7.1$ Hz, 6 H, $\text{CH}(\text{CH}_3)_2$),
15 1.20-1.24 (t, $J = 7.1$ Hz, 3 H, CH_2CH_3), 1.27-1.51 (m, 3 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 2.18-2.81 (m, 6 H, pyrrolidine ring), 3.50-3.65 (ABq, $J = 43.4$ Hz, 2 H, CH_2Ph), 4.07-4.15 (m, 2 H, CH_2CH_3), 7.21-7.30 (m, 5 H, aromatic ring); $^{13}\text{C}(\text{CDCl}_3)$:
 δ 14.22, 22.42, 22.92, 26.46, 39.89, 44.84, 49.48, 56.65, 60.07, 60.33, 60.44, 126.87, 128.19, 128.63, 138.95, 174.93; MS (CI) m/z 290 ($M+1$)⁺. Anal.
20 ($\text{C}_{18}\text{H}_{27}\text{NO}_2$) C, H, N.

***trans*-1-Benzyl-4-butylpyrrolidine-3-carboxylic acid ethyl ester (2f).** yield 82%; ^1H NMR (CDCl_3): δ 0.85 (t, $J = 7.1$ Hz, 3 H, $\text{CH}_2\text{CH}_2\text{CH}_3$), 1.20-1.24 (t, $J = 7.1$ Hz, 3 H, CH_2CH_3), 1.27-1.51 (m, 3 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 2.18-2.81 (m, 6 H, pyrrolidine ring), 3.50-3.65 (ABq, $J = 43.4$ Hz, 2 H, CH_2Ph), 4.07-4.15 (m, 2 H, CH_2CH_3), 7.20-7.30 (m, 5 H, aromatic ring); $^{13}\text{C}(\text{CDCl}_3)$: δ 13.98, 14.22,
25

-33-

19.18, 22.67, 30.19, 34.93, 41.95, 49.27, 56.75, 60.06, 60.44, 126.84, 128.18, 128.62, 139.00, 174.95; MS (CI) m/z 290 (M+1)⁺. Anal. (C₁₈H₂₇NO₂) C, H, N.

General Procedure for the Preparation of 4-Alkylpyrrolidine-3-carboxylic

acid 3a-3h. (Scheme 5) To a solution of 1-benzyl-4-alkylpyrrolidine-3-carboxylic acid ethyl ester **2a-2h** (4.42 mmol) in ethanol (75 mL) was added 20% Pd/C (0.21 g) and hydrogenated at 50 psi for 11 hours. The reaction mixture was filtered through a pad of celite. The filtrate was concentrated to give 4-alkylpyrrolidine-3-carboxylic acid ethyl ester as an oil. To the crude oil was added 3N HCl (20 mL). The reaction mixture was refluxed for 12 hours. After the solvent was evaporated at reduced pressure, the crude product was subjected to ion exchange column (Dowex 50) and recrystallized from methanol-ether to give 4-alkylpyrrolidine-3-carboxylic acid **3a-3h** as a white solid.

trans-4-Methylpyrrolidine-3-carboxylic acid (3a). yield 90%; mp 208-210°C;

¹H NMR (CD₃OD): δ 1.14 (d, J = 6.3 Hz, 3 H, CH₃), 2.42-2.54 (m, 2 H, pyrrolidine ring), 2.74-2.79 (m, 1 H, pyrrolidine ring), 3.71-3.46 (m, 3 H, pyrrolidine ring); ¹³C(CD₃OD): δ 15.77, 37.72, 48.33, 51.34, 52.75, 177.16; MS (CI) m/z 130 (M+1)⁺. Anal. (C₆H₁₁NO₂) C, H, N.

trans-4,4-Dimethylpyrrolidine-3-carboxylic acid (3b). yield 84%; mp

282-286°C; ¹H NMR (CD₃OD): δ 1.11 (s, 3 H, CH₃), 1.21 (s, 3 H, CH₃), 2.59-2.63 (m, 1 H, pyrrolidine ring), 2.94 (d, J = 11.3 Hz, 1 H, pyrrolidine ring), 3.15 (d, J = 11.3 Hz, 1 H, pyrrolidine ring), 3.36-3.41 (m, 1 H, pyrrolidine ring), 3.53-3.58 (m, 1 H, pyrrolidine ring); ¹³C(CD₃OD): δ 21.33, 25.87, 41.05, 48.21, 55.51, 56.50, 177.10; MS (CI) m/z 144 (M+1)⁺. Anal. (C₇H₁₃NO₂) C, H, N.

trans-4-Ethylpyrrolidine-3-carboxylic acid (3c). yield 78%; mp 197-199°C;

¹H NMR (CD₃OD): δ 0.98 (m, 3 H, CH₃), 1.41-1.44 (m, 1 H, CH₂CH₃), 1.65-1.70 (m, 1 H, CH₂CH₃), 2.34-2.39 (m, 1 H, pyrrolidine ring), 2.56-2.62 (m, 1 H, pyrrolidine ring), 2.80-2.88 (m, 1 H, pyrrolidine ring), 3.36-3.48 (m, 3 H,

pyrrolidine ring); $^{13}\text{C}(\text{CD}_3\text{OD})$: δ 11.10, 25.35, 44.47, 48.46, 49.65, 51.07, 177.60; MS (CI) m/z 144 ($\text{M}+1$)⁺. Anal. ($\text{C}_7\text{H}_{13}\text{NO}_2$) C, H, N.

***trans*-4-Isopropylpyrrolidine-3-carboxylic acid (3d).** yield 88%; mp

243-245°C; ^1H NMR (CD_3OD): δ 0.92 (d, $J = 6.5$ Hz, 3 H, CH_3), 0.99 (d, $J = 6.5$ Hz, 3 H, CH_3), 1.67-1.72 (m, 1 H, $\text{CH}(\text{CH}_3)_2$), 2.29-2.37 (m, 1 H, pyrrolidine ring), 2.66-2.72 (m, 1 H, pyrrolidine ring), 2.89-2.94 (m, 1 H, pyrrolidine ring), 3.31-3.45 (m, 3 H, pyrrolidine ring); $^{13}\text{C}(\text{CD}_3\text{OD})$: δ 19.00, 19.94, 30.32, 48.22, 49.20, 49.26, 49.40, 178.18; MS (CI) m/z 158 ($\text{M}+1$)⁺. Anal. ($\text{C}_8\text{H}_{15}\text{NO}_2$) C, H, N.

***trans*-4-Propylpyrrolidine-3-carboxylic acid (3e).** yield 88%; mp 223-226°C;

^1H NMR (CD_3OD): δ 0.92 (t, $J = 6.6$ Hz, 3 H, CH_3), 1.32-1.40 (m, 3 H, CH_2CH_2), 1.61 (m, 1 H, CH_2CH_2), 2.42-2.46 (m, 1 H, pyrrolidine ring), 2.55-2.60 (q, $J = 7.5$ Hz, 1 H, pyrrolidine ring), 2.80-2.85 (t, $J = 11.3$ Hz, 1 H, pyrrolidine ring), 3.38-3.47 (m, 3 H, pyrrolidine ring); $^{13}\text{C}(\text{CD}_3\text{OD})$: δ 12.96, 20.69, 34.68, 42.62, 48.45, 49.94, 51.43, 177.51; MS (CI) m/z 158 ($\text{M}+1$)⁺. Anal. ($\text{C}_8\text{H}_{15}\text{NO}_2$) C, H, N.

***trans*-4-Isobutylpyrrolidine-3-carboxylic acid (3f).** yield 86%; mp 255-257°C;

^1H NMR (CD_3OD): δ 0.89 (m, 6 H, CH_3), 1.26 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 1.51 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 1.60 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 2.52 (m, 2 H, pyrrolidine ring), 2.78 (m, 1 H, pyrrolidine ring), 3.37 (m, 2 H, pyrrolidine ring), 3.44 (m, 1 H, pyrrolidine ring); $^{13}\text{C}(\text{CD}_3\text{OD})$: δ 21.07, 22.07, 26.29, 40.81, 41.83, 48.39, 50.11, 51.78, 177.47; MS (CI) m/z 172 ($\text{M}+1$)⁺. Anal. ($\text{C}_9\text{H}_{17}\text{NO}_2$) C, H, N.

***cis*-4-Isobutylpyrrolidine-3-carboxylic acid (3g).** yield 85%; mp 260-262°C;

^1H NMR (CD_3OD): δ 0.88 (m, 6 H, CH_3), 1.25 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$),

-35-

1.47 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 1.63 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 2.49 (m, 1 H, pyrrolidine ring), 3.15 (m, 1 H, pyrrolidine ring), 3.18 (m, 1 H, pyrrolidine ring), 3.31-3.46 (m, 3 H, pyrrolidine ring; MS (CI) m/z 172 (M+1)⁺. Anal. ($\text{C}_9\text{H}_{17}\text{NO}_2$) C, H, N.

5 ***trans*-4-Butylpyrrolidine-3-carboxylic acid (3h)**. yield 85%; mp 234-237°C; ¹H NMR (CD_3OD): δ 0.89 (m, 3 H, CH_3), 1.33 (m, 5 H, $\text{CH}_2\text{CH}_2\text{CH}_2$), 1.65 (m, 1 H, $\text{CH}_2\text{CH}_2\text{CH}_2$), 2.38-2.43 (m, 1 H, pyrrolidine ring), 2.55-2.60 (q, $J = 7.5$ Hz, 1 H, pyrrolidine ring), 2.80-2.85 (t, $J = 8.8$ Hz, 1 H, pyrrolidine ring), 3.28-3.48 (m, 3 H, pyrrolidine ring); ¹³C(CD_3OD): δ 12.85, 22.33, 29.77, 32.20, 42.83, 48.39, 49.91, 51.43, 177.62; MS (CI) m/z 172 (M+1)⁺. Anal. ($\text{C}_9\text{H}_{17}\text{NO}_2$) C, H, N.

15 **3-[(E)-3-Isobutylpropenoyl]-4-(S)-phenyl-2-oxazolidinone (7a)**. (Scheme 6) To a solution of (E)-5-methyl-hex-2-enoic acid (3.2 g, 25 mmol) in toluene (20 mL) was added oxalyl chloride (4.4 mL, 50 mmol) slowly at 0°C under N_2 followed by one drop of DMF. The mixture was stirred at 22°C for 1 hour. The volatiles were removed under reduced pressure to give the desired acid chloride which was used without further purification. To a solution of NaH (0.84 g, 21 mmol) in THF (30 mL) was added a solution of (S)-(-)-4-phenyl-2-oxazolidinone (3.4 g, 21 mmol) in THF (10 mL) at 0°C. The mixture was stirred at 22°C for 1 hour. The crude acid chloride was then introduced while maintaining the temperature at 0°C. The mixture was stirred at 0°C for 1 hour and then at 22°C for an additional 12 hours. The reaction was quenched with 1N HCl aqueous solution, extracted with CHCl_3 , then dried over Na_2SO_4 . After the solvent was evaporated at reduced pressure, the crude product was subjected to column chromatography (silica gel, hexanes:ether=2:1) to give 6.25 g (100% yield) of **7a** as a white solid. mp 84-85°C; ¹H NMR (CDCl_3): δ 0.81 (d, $J = 6.8$ Hz, 6 H, $\text{CH}(\text{CH}_3)_2$), 1.68-1.78 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 2.11-2.14 (m, 2 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 4.24-4.27 (m, 1 H, oxazolidinone ring), 4.65-4.72 (t, $J = 8.8$ Hz, 1 H,

-36-

oxazolidinone ring), 5.44-5.48 (m, 1 H, oxazolidinone ring), 7.02-7.09 (m, 1 H, vinyl), 7.23-7.28 (m, 1 H, vinyl), 7.31-7.38 (m, 5 H, aromatic); $^{13}\text{C}(\text{CDCl}_3)$: δ 22.35, 22.39, 27.88, 41.82, 57.77, 69.92, 121.11, 125.95, 128.63, 129.16, 139.14, 151.10, 153.70, 164.56; MS (CI) m/z 274 ($\text{M}+1$)⁺. Anal. ($\text{C}_{16}\text{H}_{19}\text{NO}_3$)

5 C, H, N.

1-Benzyl-4-(R)-isobutyl-3-(R)-[4'-(S)-phenyl-2'-oxazolidinon-3'-yl]carbonyl]pyrrolidine (8a). (Scheme 6) To a stirred solution of 3-[(E)-3-isobutylpropenoyl]-4-(S)-phenyl-2-oxazolidinone (1.50 g, 5.50 mmol) in toluene (20 mL) was added N-benzyl-N-(methoxymethyl) trimethylsilylmethylamine (1.56 g, 6.60 mmol) at 0°C under N_2 . After 20 minutes, a solution of TFA (1 M in CH_2Cl_2 , 0.55 mmol) was added slowly at 0°C. The mixture was stirred at 0°C for 30 minutes and then at 22°C for an additional 12 hours. The reaction was quenched with H_2O , extracted with CHCl_3 , then dried over MgSO_4 . The solvent was evaporated to dryness, and the oily residue was subjected to column chromatography (silica gel, hexanes:ether=2:1) to give 1.37 g (62% yield) of **8a** as a white solid. ^1H NMR (CDCl_3): δ 0.84-0.86 (m, 6 H, $\text{CH}(\text{CH}_3)_2$), 1.26-1.29 (m, 2 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 1.42-1.47 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 2.08 (t, $J = 7.3$ Hz, 1 H, pyrrolidine ring), 2.62 (dd, $J = 9.8$ Hz, 4.6 Hz, 1 H, pyrrolidine ring), 2.83-2.94 (m, 3 H, pyrrolidine ring), 3.37-3.67 (ABq, 2 H, CH_2Ph), 3.68-3.72 (m, 1 H, pyrrolidine ring), 4.16-4.19 (m, 1 H, oxazolidinone ring), 4.63 (t, $J = 9.0$ Hz, 1 H, oxazolidinone ring), 5.40 (m, 1 H, oxazolidinone ring), 7.18-7.36 (m, 5 H, aromatic); $^{13}\text{C}(\text{CDCl}_3)$: δ 22.46, 23.05, 26.72, 37.00, 44.07, 49.41, 57.48, 57.85, 59.84, 60.54, 69.87, 125.67, 126.80, 128.21, 128.48, 128.65, 129.25, 139.01, 139.05, 153.55, 173.71; MS (CI) m/z 407 ($\text{M}+1$)⁺. Anal. ($\text{C}_{25}\text{H}_{30}\text{N}_2\text{O}_3$) C, H, N.

25 **trans-4-(R)-Isobutylpyrrolidine-3-(R)-carboxylic acid (10a).** (Scheme 6) To a solution of 1-benzyl-4-(R)-isobutyl-3-(R)-[4'-(S)-phenyl-2'-oxazolidinon-3'-yl]carbonyl]pyrrolidine (1.37g, 3.37 mmol) in THF (30 mL) was added a solution of LiOH (1 M in H_2O , 8.44 mmol) and H_2O_2 (30%, 6.75 mmol) in H_2O (10 mL)

-37-

at 0°C slowly. The reaction mixture was stirred at 0°C for 1 hour, then diluted with water (40 mL). Sodium sulfite (0.85 g, 6.75 mmol) was added, and the mixture was extracted with ethyl acetate. The aqueous phase was adjusted to pH 5.0 with KH_2PO_4 (1.51 g, 11.1 mmol) and 10% HCl. This solution was
5 extracted with isopropyl alcohol:methylene chloride (1:3), which was dried over Na_2SO_4 and concentrated to afford 0.88 g of 1-benzyl-4-(R)-isobutylpyrrolidine-3-(R)-carboxylic acid which was used without further purification. To a solution of this carboxylic acid (0.72 g) in ethanol (55 mL) was added 20% Pd/C (0.11 g) and hydrogenated at 50 psi for 11 hours. The reaction mixture was filtered through
10 a pad of celite. After the solvent was evaporated at reduced pressure, the crude product was subjected to ion exchange column (Dowex 50) and recrystallized from methanol-ether to give 0.33 g (71% yield) of **10a** as a white solid.

$[\alpha]_D = +44.8^\circ$; mp 236-239°C; ^1H NMR (CD_3OD): δ 0.89 (m, 6 H, CH_3), 1.26 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 1.51 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 1.60 (m, 1 H, $\text{CH}_2\text{CH}(\text{CH}_3)_2$), 2.52 (m, 2 H, pyrrolidine ring), 2.78 (m, 1 H, pyrrolidine ring),
15 3.37 (m, 2 H, pyrrolidine ring), 3.44 (m, 1 H, pyrrolidine ring); ^{13}C (CD_3OD): δ 21.07, 22.07, 26.29, 40.81, 41.83, 48.39, 50.11, 51.78, 177.47; MS (CI) m/z 172 ($\text{M}+1$)⁺. Anal. ($\text{C}_9\text{H}_{17}\text{NO}_2$) C, H, N.

3-[(E)-3-Isobutylpropenoyl]-4-(R)-phenyl-2-oxazolidinone (7b). (Scheme 6) To
20 a solution of (E)-5-methyl-hex-2-enoic acid (1.77 g, 13.8 mmol) in toluene (20 mL) was added oxalyl chloride (2.4 mL, 27.6 mmol) slowly at 0°C under N_2 followed by one drop of DMF. The mixture was stirred at 22°C for 1 hour. The volatiles were removed under reduced pressure to give the desired acid chloride which was used without further purification. To a solution of NaH
25 (0.37 g, 9.2 mmol) in THF (30 mL) was added a solution of (R)-(-)-4-phenyl-2-oxazolidinone (1.5 g, 9.2 mmol) in THF (10 mL) at 0°C. The mixture was stirred at 22°C for 1 hour. The crude acid chloride was then introduced while maintaining the temperature at 0°C. The mixture was stirred at 0°C for 1 hour and then at 22°C for an additional 12 hours. The reaction was quenched with 1N HCl
30 aqueous solution, extracted with CHCl_3 , then dried over Na_2SO_4 . After the

-38-

solvent was evaporated at reduced pressure, the crude product was subjected to column chromatography (silica gel, hexanes:acetone=3:1) to give 2.5 g (100% yield) of **7b** as a white solid. mp 84-85°C; ¹H NMR (CDCl₃): δ 0.81 (d, *J* = 6.8 Hz, 6 H, CH(CH₃)₂), 1.68-1.78 (m, 1 H, CH₂CH(CH₃)₂), 2.11-2.14 (m, 2 H, CH₂CH(CH₃)₂), 4.24-4.27 (m, 1 H, oxazolidinone ring), 4.65-4.72 (t, *J* = 8.8 Hz, 1 H, oxazolidinone ring), 5.44-5.48 (m, 1 H, oxazolidinone ring), 7.02-7.09 (m, 1 H, vinyl), 7.23-7.28 (m, 1 H, vinyl), 7.31-7.38 (m, 5 H, aromatic); ¹³C(CDCl₃): δ 22.35, 22.39, 27.88, 41.82, 57.77, 69.92, 121.11, 125.95, 128.63, 129.16, 139.14, 151.10, 153.70, 164.56; MS (CI) *m/z* 274 (M+1)⁺. Anal. (C₁₆H₁₉NO₃) C, H, N.

1-Benzyl-4-(S)-isobutyl-3-(S)-[4'-(R)-phenyl-2'-oxazolidinon-3'-yl]carbonyl]pyrrolidine (8b). To a stirred solution of 3-[(E)-3-isobutylpropenoyl]-4-(R)-phenyl-2-oxazolidinone (1.50 g, 5.50 mmol) in toluene (20 mL) was added N-benzyl-N-(methoxymethyl) trimethylsilylmethylamine (1.56 g, 6.60 mmol) at 0°C under N₂. After 20 minutes, a solution of TFA (1 M in CH₂Cl₂, 0.55 mmol) was added slowly at 0°C. The mixture was stirred at 0°C for 30 minutes and then at 22°C for an additional 12 hours. The reaction was quenched with H₂O, extracted with CHCl₃, then dried over MgSO₄. The solvent was evaporated to dryness, and the oily residue was subjected to column chromatography (silica gel, hexanes:ether=2:1) to give 1.45 g (65% yield) of **8b** as a white solid. ¹H NMR (CDCl₃): δ 0.84-0.86 (m, 6 H, CH(CH₃)₂), 1.26-1.29 (m, 2 H, CH₂CH(CH₃)₂), 1.42-1.47 (m, 1 H, CH₂CH(CH₃)₂), 2.08 (t, *J* = 7.3 Hz, 1 H, pyrrolidine ring), 2.62 (dd, *J* = 9.8 Hz, 4.6 Hz, 1 H, pyrrolidine ring), 2.83-2.94 (m, 3 H, pyrrolidine ring), 3.37-3.67 (ABq, 2 H, CH₂Ph), 3.68-3.72 (m, 1 H, pyrrolidine ring), 4.16-4.19 (m, 1 H, oxazolidinone ring), 4.63 (t, *J* = 9.0 Hz, 1 H, oxazolidinone ring), 5.40 (m, 1 H, oxazolidinone ring), 7.18-7.36 (m, 5 H, aromatic); ¹³C(CDCl₃): δ 22.46, 23.05, 26.72, 37.00, 44.07, 49.41, 57.48, 57.85, 59.84, 60.54, 69.87, 125.67, 126.80, 128.21, 128.48, 128.65, 129.25, 139.01, 139.05, 153.55, 173.71; MS (CI) *m/z* 407 (M+1)⁺. Anal. (C₂₅H₃₀N₂O₃) C, H, N.


-39-

***trans*-4-(S)-Isobutylpyrrolidine-3-(S)-carboxylic acid (10b).** (Scheme 6) To a solution of 1-benzyl-4-(S)-isobutyl-3-(S)-[4'-(R)-phenyl-2'-oxazolidinon-3'-yl]carbonyl]pyrrolidine (1.44 g, 3.56 mmol) in THF (30 mL) was added a solution of LiOH (1 M in H₂O, 8.89 mmol) and H₂O₂ (30%, 7.11 mmol) in H₂O (10 mL) at 0°C slowly. The reaction mixture was stirred at 0°C for 1 hour, then diluted with water (40 mL). Sodium sulfite (0.89 g, 7.11 mmol) was added, and the mixture was extracted with ethyl acetate. The aqueous phase was adjusted to pH 5.0 with KH₂PO₄ (1.59 g, 11.7 mmol) and 10% HCl. This solution was extracted with isopropyl alcohol:methylene chloride (1:3), which was dried over Na₂SO₄ and concentrated to afford 0.93 g of 1-benzyl-4-(S)-isobutylpyrrolidine-3-(S)-carboxylic acid which was used without further purification. To a solution of this carboxylic acid (0.94 g) in ethanol (55 mL) was added 20% Pd/C (0.21 g) and hydrogenated at 50 psi for 11 hours. The reaction mixture was filtered through a pad of celite. After the solvent was evaporated at reduced pressure, the crude product was subjected to ion exchange column (Dowex 50) and recrystallized from methanol-ether to give 0.43 g (70% yield) of **10b** as a white solid.

[α]_D = -45.8°; mp 251-254°C; ¹H NMR (CD₃OD): δ 0.89 (m, 6 H, CH₃), 1.26 (m, 1 H, CH₂CH(CH₃)₂), 1.51 (m, 1 H, CH₂CH(CH₃)₂), 1.60 (m, 1 H, CH₂CH(CH₃)₂), 2.52 (m, 2 H, pyrrolidine ring), 2.78 (m, 1 H, pyrrolidine ring), 3.37 (m, 2 H, pyrrolidine ring), 3.44 (m, 1 H, pyrrolidine ring); ¹³C(CD₃OD): δ 21.07, 22.07, 26.29, 40.81, 41.83, 48.39, 50.11, 51.78, 177.47; MS (CI) *m/z* 172 (M+1)⁺. Anal. (C₉H₁₇NO₂) C, H, N.

-40-
CLAIMS

1. A compound of formula I




I

- 5 or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein
R₁ is hydrogen or a straight or branched alkyl of from 1 to 5 carbons;
R₂ is a straight or branched alkyl of from 1 to 5 carbons; and
R₁ and R₂ when taken together form a carbocyclic ring of from 3 to
7 atoms.
- 10 2. A compound according to Claim 1 wherein
R₁ is H, methyl, or ethyl; and
R₂ is methyl or ethyl.
3. A compound according to Claim 1 and selected from (cis)-4-isobutyl-
pyrrolidine-3-carboxylic acid and (trans)-4-isobutyl-pyrrolidine-
3-carboxylic acid.
- 15 4. A compound according to Claim 1 wherein R₁ and R₂ are taken to form a
carbocyclic ring of from 3 to 7 atoms.
5. A compound according to Claim 1 and selected from where R₁ and R₂
form a five or six membered ring.

-41-

6. A compound of Formula I



IA

or a pharmaceutically acceptable salt thereof wherein R₄ is a alkyl of 3 or 4 carbons.

- 5 7. A compound according to Claim 6 and selected from:
trans-4-isopropylpyrrolidine-3-carboxylic acid;
trans-4-propyl-pyrrolidine-3-carboxylic acid; and
trans-4-butyl-pyrrolidine-3-carboxylic acid.
- 10 8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
9. A method for treating epilepsy comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 15 10. A method for treating faintness attacks, hypokinesia, and cranial disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 20 11. A method for treating neurodegenerative disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
12. A method for treating depression comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.

-42-

13. A method for treating anxiety comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 5 14. A method for treating panic comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
15. A method for treating pain comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 10 16. A method for treating neuropathological disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/18258

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D207/16 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 15108 A (LILLY CO ELI) 23 May 1996 (1996-05-23) abstract; claims; example 1 ---	1,6,8-16
A	WO 96 06095 A (ABBOTT LAB) 29 February 1996 (1996-02-29) page 79 -page 80; example 1 claims 19,20,25,26 ---	1,6,8-16
A	US 4 087 544 A (SATZINGER GERHARD ET AL) 2 May 1978 (1978-05-02) cited in the application column 3 -column 8; claim 1; examples -----	1,6,8-16

☐ Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 January 2000

Date of mailing of the international search report

19/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Paisdor, 8

INTERNATIONAL SEARCH REPORT

i. national application No.

PCT/US 99/ 18258

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 9-16
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 9-16
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/18258

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9615108 A	23-05-1996	US 5473077 A	05-12-1995
		AU 4281896 A	06-06-1996
		CA 2204767 A	23-05-1996
		EP 0711755 A	15-05-1996
		JP 10508855 T	02-09-1998
WO 9606095 A	29-02-1996	US 5767144 A	16-06-1998
		AU 2034499 A	03-06-1999
		AU 711832 B	21-10-1999
		AU 3213795 A	14-03-1996
		CA 2195677 A	29-02-1996
		EP 0776324 A	04-06-1997
		JP 10504565 T	06-05-1998
		US 5622971 A	22-04-1997
		US 5731434 A	24-03-1998
US 4087544 A	02-05-1978	DE 2460891 A	01-07-1976
		AT 340892 B	10-01-1978
		AT 975075 A	15-05-1977
		AU 8774175 A	23-06-1977
		BE 836835 A	18-06-1976
		CA 1052811 A	17-04-1979
		CH 612665 A	15-08-1979
		CH 612666 A	15-08-1979
		CH 612664 A	15-08-1979
		DE 2543821 A	14-04-1977
		DK 581475 A,B,	22-01-1976
		ES 443723 A	16-04-1977
		FI 753613 A,B,	22-06-1976
		FR 2294697 A	16-07-1976
		GB 1465229 A	23-02-1977
		IE 42382 B	30-07-1980
		JP 941538 C	20-02-1979
		JP 51088940 A	04-08-1976
		JP 53024064 B	18-07-1978
		LU 74058 A	20-07-1976
		MX 4721 E	13-08-1982
		MX 4691 E	02-08-1982
		NL 7514900 A,B,	23-06-1976
		SE 423385 B	03-05-1982
		SE 7514442 A	22-06-1976
		US 4024175 A	17-05-1977

THIS PAGE BLANK (USPTO)